Facebook
Twitter
Telegram
Report an Error4D Molecular Therapeutics Financial Statements 2011-2024 | FDMT
Annual Financial Statements 4D Molecular Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
1.09 B | 558 M | 380 M | 530 M | - | - | - | - | - | - | - | - | - |
Shares |
39.1 M | 32.4 M | 27.7 M | 12.5 M | - | - | - | - | - | - | - | - | - |
Historical Prices |
28 | 17.2 | 13.7 | 42 | - | - | - | - | - | - | - | - | - |
Net Income |
-101 M | -107 M | -71.3 M | -56.7 M | -49.3 M | -9.55 M | -11.2 M | - | - | - | - | - | - |
Revenue |
20.7 M | 3.13 M | 18 M | 13.6 M | 6.99 M | 14.1 M | 5.79 M | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | 13.6 K | - | - | - | - | - | - | - | - | - |
Operating Income |
-113 M | -110 M | -71.3 M | -56.7 M | -50.8 M | - | - | - | - | - | - | - | - |
Interest Expense |
-181 K | -35 K | -121 K | -181 K | -46 K | - | - | - | - | - | - | - | - |
EBITDA |
-109 M | -108 M | -69.8 M | -55.2 M | -44.6 M | -9.7 M | -10.6 M | - | - | - | - | - | - |
Operating Expenses |
134 M | 113 M | 89.4 M | 70.3 M | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
36.5 M | 32.9 M | 28 M | 17.2 M | 13.9 M | 6.17 M | 3.49 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement 4D Molecular Therapeutics
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
49.3 M | 43.1 M | 42.3 M | 38.3 M | 32.7 M | 32.6 M | 32.4 M | 32.3 M | 32.2 M | 32.2 M | 27 M | 26.7 M | 26.7 M | 26.7 M | 5.2 M | 5.18 M | 5.18 M | 5.18 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-32.4 M | - | -10.3 M | -29.6 M | -28.7 M | - | -25.7 M | -28.1 M | -26.3 M | - | -22.2 M | -7.59 M | -16.4 M | - | -7.83 M | -15.2 M | -13.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
28 K | - | 20.2 M | 239 K | 298 K | - | 500 K | 162 K | 1.22 M | - | 1.37 M | 14.6 M | 2 M | - | 7.42 M | 3.63 M | 3.54 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-38.1 M | - | -14 M | -32.1 M | -30.1 M | - | -26.5 M | -28.4 M | -26.4 M | - | -22.7 M | -7.6 M | -16.3 M | - | -7.82 M | -15.1 M | -13.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
-10 K | - | -158 K | 8 K | -19 K | - | 9 K | - | -46 K | - | -13 K | - | -101 K | - | -21 K | -18 K | -13 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-37 M | - | -12.9 M | -31 M | -29.1 M | - | -26 M | -27.9 M | -26 M | - | -21.5 M | -6.84 M | -15.9 M | - | -6.74 M | -14.4 M | -12.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
38.2 M | - | 34.2 M | 32.4 M | 30.4 M | - | 27 M | 28.6 M | 27.6 M | - | 24 M | 22.2 M | 18.3 M | - | 15.2 M | 18.8 M | 16.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
10.3 M | - | 9.11 M | 8.79 M | 7.99 M | - | 8.06 M | 8.17 M | 8.23 M | - | 8.19 M | 6.95 M | 5.54 M | - | 3.68 M | 3.06 M | 3.65 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency